Lori Delgaudio, DO
Obstetrics & Gynecology · Wilkes Barre, PANPI 1427093079
Payments from drug & device makers
Across 82 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$442
- Astellas Pharma US Inc$372
- Exeltis, USA Inc.$144
- Mayne Pharma Commercial LLC$102
- Millicent US Inc$92
- Therapeuticsmd, Inc.$69
- plus $422 from 16 others
What the payments were for
- Food & beverage$1,28178%
- Education$36322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $442 |
| Astellas Pharma US Inc | 7 | $372 |
| Exeltis, USA Inc. | 9 | $144 |
| Mayne Pharma Commercial LLC | 6 | $102 |
| Millicent US Inc | 5 | $92 |
| Therapeuticsmd, Inc. | 4 | $69 |
| Roche Diagnostics Corporation | 4 | $64 |
| Avion Pharmaceuticals | 4 | $52 |
| Evofem Biosciences, Inc. | 2 | $33 |
| AMAG Pharmaceuticals, Inc. | 2 | $30 |
| Organon | 2 | $29 |
| Axonics, Inc. | 1 | $25 |
| Teleflex LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| Minerva Surgical, Inc | 1 | $20 |
| Bioprotect Medical, Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Boston Scientific | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$1,645 in reported general payments places this provider in the 80th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 29 | $9,708 |
| Estradiol | 56 | $2,940 |
| Clobetasol Propionate | 65 | $2,768 |
| Medroxyprogesterone Acetate | 46 | $1,646 |
| ValacyclovirValacyclovir Hcl | 35 | $1,030 |
| DottiEstradiol | 11 | $696 |
| VolneaDesog-E.Estradiol/E.Estradiol | 14 | $465 |
| Nystatin | 16 | $173 |
| JunelNorethindrone Ac/Eth Estradiol | 12 | $118 |
| Tri-EstaryllaNorgestimate-Ethinyl Estradiol | 14 | $114 |
| Fluconazole | 19 | $77 |
| Alendronate Sodium | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Wilkes Barre
- Marvin KalaferJenkintown$4.6M
- Catherine ChappellPittsburgh$4.3M
- Stephen KlaskoPhiladelphia$2.2M
- Robert EdwardsPittsburgh$1.9M
- Stephanie SoberPhiladelphia$1.8M
- Michael ScutellaErie$1.7M
- Sarah TaylorPittsburgh$1.3M
- Andrea RoePhiladelphia$925K
- Beatrice ChenPittsburgh$549K
- Courtney SchreiberPhiladelphia$519K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.